Background:

T-5224 is a non-peptidic, small molecule and novel inhibitor of c-Fos/AP-1 [1].

T-5224 has shown the specific inhibition in a c-Fos/AP-1promoter-luciferase assay, without affecting the levels of c-Fos family protein members themselves. In addition, T-5224 has been reported to selectively inhibit the DNA binding activity of c-Fos/c-Jun, without affecting those of other transcription factors(C/EBPα and ATF-2, MyoD, Sp-1 and NF-κB/p65). Some research has been suggested that T-5224 potently suppressed the development of collagen-induced arthritis (CIA). Besides, T-5224 has been evidenced to inhibit the expression of nuclear factor of activated T-cells (NFAT) and osteoclastogenesis of the macrophage-osteoclast precursor RAW264.7cells induced by receptor activator of NF-κB ligand (RANKL). Apart from these, T-5224 has been noted to inhibit in-vitro production of the mediators (MMP-1, MMP-3, IL-6 and TNF-α) in IL-1β-stimulated human synovial SW982 cells with the mean IC50 of about 10μM. In the in vivo pharmacokinetic analysis, the ED50 of T-5224 is about 1-10mg/kg, and the Cmax is 0.03-0.5μM [1].

参考文献:
[1] Aikawa Y1, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, Hirono S, Shiozawa S. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol. 2008 Jul;26(7):817-23.